Opioid Receptor Agonists - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 working days
DelveInsight’s, “Opioid Receptor Agonists - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Opioid Receptor Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Opioid Receptor Agonists: Overview
Opioids are a group of analgesic agents commonly used in clinical practice. Opioids produce their pharmacological effects through the activation of opioid receptors, which include three main types, mu (MOR), delta (DOR) and kappa (KOR) of which the MOR type is the primary target of most clinically used opioid analgesics. Opioid agonists bind to G-protein coupled receptors to cause cellular hyperpolarisation. Most clinically relevant opioid analgesics bind to MOP receptors in the central and peripheral nervous system in an agonist manner to elicit analgesia. Opioids may also be classified according to their mode of synthesis into alkaloids, semi-synthetic and synthetic compounds.
'Opioid Receptor Agonists - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Opioid Receptor Agonists pipeline landscape is provided which includes the disease overview and Opioid Receptor Agonists treatment guidelines. The assessment part of the report embraces, in depth Opioid Receptor Agonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid Receptor Agonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Opioid Receptor Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Opioid Receptor Agonists Emerging Drugs
Further product details are provided in the report……..
Opioid Receptor Agonists: Therapeutic Assessment
This segment of the report provides insights about the different Opioid Receptor Agonists drugs segregated based on following parameters that define the scope of the report, such as:
Opioid Receptor Agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Opioid Receptor Agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid Receptor Agonists drugs.
Opioid Receptor Agonists Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Opioid Receptor Agonists - Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Opioid Receptor Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Opioid Receptor Agonists: Overview
Opioids are a group of analgesic agents commonly used in clinical practice. Opioids produce their pharmacological effects through the activation of opioid receptors, which include three main types, mu (MOR), delta (DOR) and kappa (KOR) of which the MOR type is the primary target of most clinically used opioid analgesics. Opioid agonists bind to G-protein coupled receptors to cause cellular hyperpolarisation. Most clinically relevant opioid analgesics bind to MOP receptors in the central and peripheral nervous system in an agonist manner to elicit analgesia. Opioids may also be classified according to their mode of synthesis into alkaloids, semi-synthetic and synthetic compounds.
'Opioid Receptor Agonists - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Opioid Receptor Agonists pipeline landscape is provided which includes the disease overview and Opioid Receptor Agonists treatment guidelines. The assessment part of the report embraces, in depth Opioid Receptor Agonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Opioid Receptor Agonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Opioid Receptor Agonists R&D. The therapies under development are focused on novel approaches to treat/improve Opioid Receptor Agonists.
This segment of the Opioid Receptor Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Opioid Receptor Agonists Emerging Drugs
- LTX-03: Acura Pharmaceuticals
- TRV-734: Trevena
Further product details are provided in the report……..
Opioid Receptor Agonists: Therapeutic Assessment
This segment of the report provides insights about the different Opioid Receptor Agonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Opioid Receptor Agonists
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Opioid Receptor Agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Opioid Receptor Agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Opioid Receptor Agonists drugs.
Opioid Receptor Agonists Report Insights
- Opioid Receptor Agonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Opioid Receptor Agonists drugs?
- How many Opioid Receptor Agonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Opioid Receptor Agonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Opioid Receptor Agonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Opioid Receptor Agonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Trevena
- Titan Pharmaceuticals
- Lumosa Therapeutics
- Astraea Therapeutics
- Alar Pharmaceuticals
- Ensysce Biosciences
- TRV-734
- TP-2021
- TRV-250
- LT5001
- ALA-1000
- PF 614
Introduction
Executive Summary
Opioid Receptor Agonists: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
LTX 03: Acura Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
TRV-734: Trevena
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Opioid Receptor Agonists Key Companies
Opioid Receptor Agonists Key Products
Opioid Receptor Agonists- Unmet Needs
Opioid Receptor Agonists- Market Drivers and Barriers
Opioid Receptor Agonists- Future Perspectives and Conclusion
Opioid Receptor Agonists Analyst Views
Opioid Receptor Agonists Key Companies
Appendix
Executive Summary
Opioid Receptor Agonists: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
LTX 03: Acura Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
TRV-734: Trevena
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Opioid Receptor Agonists Key Companies
Opioid Receptor Agonists Key Products
Opioid Receptor Agonists- Unmet Needs
Opioid Receptor Agonists- Market Drivers and Barriers
Opioid Receptor Agonists- Future Perspectives and Conclusion
Opioid Receptor Agonists Analyst Views
Opioid Receptor Agonists Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Opioid Receptor Agonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Opioid Receptor Agonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Opioid Receptor Agonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Opioid Receptor Agonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
